PANC-1 pancreatic cancer cell proliferation (PANC-1)

PANC-1 is a well-established human pancreatic cancer cell line derived from a 56-year-old male with a ductal adenocarcinoma in the head of the pancreas (ATCC, CRL-1469). It is widely utilized in oncology research as a model for pancreatic ductal adenocarcinoma (PDAC), characterized by its adherent epithelial morphology and genetic profile including KRAS (G12D) and TP53 mutations (Gradiz et al., 2016). The term 'PANC-1 pancreatic cancer cell proliferation' refers to a biological process or phenotypic assay used to measure the growth-inhibitory effects of potential therapeutic agents. Because it is a whole-cell system, it represents the integrated response of multiple signaling pathways rather than a single molecular target like a receptor or enzyme. Researchers use this model to evaluate the potency of cytotoxic drugs, such as gemcitabine, and novel targeted therapies in inhibiting cancer cell expansion (Deer et al., 2010). While essential for early-stage drug discovery, PANC-1 is known for its relative resistance to standard chemotherapy, making it a valuable tool for studying drug resistance mechanisms in pancreatic cancer.

Other names

PANC-1 cell linePANC1Pancreatic epithelioid carcinoma cell linePANC-1 proliferation assay

As a phenotypic readout rather than a single molecule, the mechanism of action involves the inhibition of various intracellular pathways including DNA synthesis, microtubule assembly, and oncogenic signaling (e.g., KRAS/MAPK and PI3K/AKT pathways) to arrest the cell cycle or induce apoptosis (Deer et al., 2010).